INTRODUCTION
Despite the recent stage migration in renal cell carcinoma (RCC) with an increased incidence of small, localized tumours, the detection rate of advanced-stage disease has not diminished [1] . Historically, extension of RCC into the inferior vena cava (IVC) has been reported in 5-10% of patients [2, 3] . Slightly lower rates of IVC involvement (3-7%) are reported in contemporary series from the Memorial Sloan-Kettering Cancer Center (MSKCC) and the Mayo Clinic [4, 5] . Surgical resection is required, and in some cases is sufficient, for the cure of such advanced disease. In one large series, the 5-year cancerspecific survival after radical nephrectomy and IVC thrombectomy was 32%; patients at lower risk (free of distant metastasis at surgery) enjoyed better outcomes (5-year cancer-specific survival of 59%) [5] .
Initial descriptions of the thrombectomy technique describe reliance upon cardiopulmonary bypass and, in some cases, hypothermic circulatory arrest for the resection of thrombi involving the intra-and supra-hepatic IVC [2, 3, 6] . Subsequently, venovenous bypass techniques were described with the same goal: obtaining a bloodless operative field to facilitate complex IVC resection and reconstruction [7] [8] [9] . Earlier in this decade, investigators at the University of Miami began to describe the application of liver transplantation techniques to aid in the dissection of the intra-and supra-hepatic IVC, eliminating the need for circulatory bypass in their hands [10, 11] .
Despite advances in targeted systemic therapy, surgical resection remains the critical component in the care of patients with locally
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B J U I N T E R N A T I O N A L
What's known on the subject? and What does the study add? Renal tumours with caval thrombus are relatively rare. Surgical management is the standard of care for lesions of this nature. Small series have been published by other groups, but our understanding of the optimal management continues to evolve.
We present the Memorial Sloan-Kettering Cancer Center series, with a discussion of techniques and complications. Of interest, we include several patients with high-level caval thrombi which were managed without bypass, supporting previous publications by the group from University of Miami.
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advanced RCC, including those with IVC thrombi. As described, the technique continues to evolve. In 1991 Burt [12] reported the initial experience with IVC thrombectomy without cardiovascular bypass at MSKCC in nine patients. In the present study, we report our updated single-institution experience with radical nephrectomy and off-bypass IVC thrombectomy, with attention to intraoperative findings, postoperative morbidity and mortality, and oncological outcomes.
PATIENTS AND METHODS
After institutional review board approval, we performed a retrospective review of our prospectively maintained nephrectomy database. We identified patients who had undergone radical nephrectomy with IVC thrombectomy without circulatory bypass. Patients with thrombi involving only the renal vein were excluded. We stratified patients by thrombus level at the time of surgery as previously described by Nesbitt et al. [3] in 1997 ( Fig. 1) , and also by surgical approach to the IVC (IVC controlled above vs below the liver). Data were reported regarding clinical presentation, intraoperative findings, tumour pathology, postoperative course and oncological outcomes. Complications were recorded, categorized and graded using a modified version of the Clavien system [13] as described previously (Table 1 ) [14] . Complication data were confirmed via careful review of all patient charts and outpatient notes. Complications were recorded up to 30 days after surgery. Due to the nature of the procedure and expected blood loss, we excluded transfusion requirement as a complication, and report that data separately. Thromboembolic events (deep vein thrombosis or pulmonary embolus) were radiographically confirmed. Ileus was defined as the inability to tolerate oral feeding by postoperative day 5 or nausea, vomiting or distension requiring nasogastric drainage, fluid support or parenteral nutrition. Complication grades ≥ 3 are considered major complications.
Descriptive statistics were compiled for all pre-and postoperative findings. Survival analysis was by the Kaplan-Meier technique and included all patients surviving the day of surgery with adequate ( > 30 days) follow-up in survivors. Univariate predictors of survival were determined using the log-rank test. P < 0.05 was considered to indicate statistical significance and all analyses were two-tailed. Multivariate analyses were not attempted due to the small number of patients and events. All statistical calculations were carried out using Stata 8.2 (College Station, TX, USA). Table 2 .
RESULTS
Between
SURGICAL TECHNIQUE AND INTRAOPERATIVE FINDINGS
Operative details are recorded in Table 3 . Detailed information regarding patients with level 3/4 thrombi can be found in Level 1 and 2 thrombi were approached through a variety of incisions (sub-costal, thoraco-abdominal, hemi-chevron, chevron, flank) depending upon surgeon preference. Infra-hepatic thrombi required vascular control of the infra-renal IVC, contralateral renal vein, and supra-renal IVC followed by cavotomy and tumour extraction. The infrahepatic approach was used successfully in one level 3 and one level 4 thrombus deemed freely mobile at resection. In both cases the thrombi were felt not to be adherent within the IVC based on MRI. Tourniquets were placed on the infra-renal IVC, contralateral renal vein, and supra-renal IVC, but the suprarenal tourniquet was not tightened. The level 3 thrombus was gently drawn back into the infra-hepatic IVC before cavotomy, and the tourniquet was cinched above it. The level 4 thrombus was evaluated once the IVC was exposed above the liver and was thought to be freely mobile. The cavotomy was performed and the thrombus withdrawn, aided by the back-bleeding from the suprarenal vena cava. Both thrombi were withdrawn intact without embolization (see Table 4 for further details).
In all, six of 10 level 3/4 thrombi were addressed via a chevron incision, a thoracoabdominal approach was used in three, and one patient with a left-sided IVC required a combined approach via chevron incision and median sternotomy. In all cases, attempts were made to mobilize the kidney and ligate the renal artery before addressing the IVC thrombus. In all but one case (median sternotomy for adequate access to the intrapericardial IVC in a patient with aberrant anatomy), level 3/4 thrombi that could not be addressed solely by an infra-hepatic approach were accessed via mobilization of the liver and a trans-diaphragmatic approach to the intra-pericardial IVC where necessary. A vascular clip was then placed around the IVC at this level, often left in the open position. A Rumel tourniquet was used if the surgeon preferred. Manual compression or the Rumel tourniquet could then be used in combination with the Pringle manoeuvre to control retrograde flow as the IVC was opened and the thrombus extracted. Retrograde flow was re-established before closure of the cavotomy to flush all tumour debris from the IVC. Transoesophageal echocardiography (TEE) was available but not routinely used. In all patients with level 3/4 thrombi, thoracic surgery was involved in preoperative planning and the operation itself. Detailed description of the surgical approach and outcome for each of the level 3/4 patients is shown in Table 4 .
HOSPITALIZATION AND COMPLICATIONS
The median (IQR) length of stay was 7 (5-11) days. Transfusions (autologous or nonautologous blood) were necessary in 51 (65%) patients, with a median (IQR) of three (two to seven) units transfused in those receiving blood. There were no intraoperative mortalities. Four patients died during the 30-day postoperative period (three in hospital, one after discharge). One additional death occurred at 33 days after surgery, after a prolonged postoperative intensive care stay, and is included as a postoperative mortality in the present analysis [total of five (6%) postoperative mortalities]. No patient with a level 3/4 thrombus died within the 30-day postoperative period. Complication data were available for 77 patients. Fifty-five complications were noted in 33 (43%) patients, but major complications were seen in only 14 (18%). Complications are presented by thrombus level in Table 5 . Cardiac and pulmonary complications were most common overall. Severe pulmonary complications were usually respiratory failure requiring reintubation, often as part of multi-organ system failure, and were the most common cause of death in the postoperative period. Four patients were reported with ileus, one of whom required total parenteral nutrition; three patients required haemodialysis and one had documented pulmonary embolus. After surgery, four (5%) patients had documented emergency room visits and three (4%) had documented re-admissions.
PATHOLOGICAL FINDINGS
The median (IQR) tumour diameter was 9.5 (8-12.2) cm with the majority (87%) found to be conventional clear cell cancer. Lymph node dissection was documented in 62 (79%) patients, with positive nodes found in 11/62 (18%). The median (IQR) node count was eight (three to 16) among those undergoing lymphadenectomy. A positive soft tissue surgical margin (not venous margin) was documented in six (8%) patients. Detailed pathological information is reported in Table 6 .
ONCOLOGICAL OUTCOMES
In all, 65 (83%) patients were deemed completely resected at the time of surgery, including seven of 10 patients with level 3/4 thrombi; four of 15 patients with known distant (non-nodal) metastases underwent complete metastasectomy, including one patient with an adrenal metastasis identified and resected at surgery. There were 62 of 65 completely resected patients who had postoperative follow-up (two expired before discharge and one was lost to follow-up); of these, 27 (41%) experienced disease recurrence. There were six local recurrences and 25 distant recurrences. The median recurrence-free survival was 87 months; the (18) 1 (4) 9 (21) 4 (40)
*Some patients had more than one major or minor complication.
median follow-up for those not experiencing an event was 55.5 months.
The median overall survival for the entire cohort was 55.5 months; the median followup time for survivors was 51 months (Fig. 2) . Univariate predictors of survival with 5-year survival probabilities are reported in Table 7 .
DISCUSSION
Complete surgical resection remains the only reliable means of achieving cure in patients with advanced RCC. Historically, large series report 5-year cancer-specific survival rates of 46-51% in locally advanced disease ( ≥ T3a) with surgery alone [15, 16] . Targeted systemic therapies could extend the survival of patients with metastatic RCC [17] , and could benefit patients with locally advanced disease as well [18] . The most appropriate application of targeted therapy and surgery in treating locally advanced or distantly metastatic RCC has not been clearly defined. Studies assessing the efficacy of cytoreduction before interferon-alpha immunotherapy have shown a benefit with maximal surgical debulking [19, 20] . Prospective clinical trials are needed to assess the role of cytoreductive nephrectomy in conjunction with contemporary targeted therapies.
Surgical resection offers some patients with IVC extension of their renal tumours the opportunity for long-term survival. In 2004 Rabbani et al. [4] reported the MSKCC experience with 31 patients who had IVC tumour extension. As part of a larger study evaluating tumour histology in patients with renal vein or IVC involvement, they presented a 5-year actuarial recurrence-free probability of 59% for the IVC thrombus population. Lymph node status, involvement of contiguous structures and the presence of distant metastasis at diagnosis have been shown to impact postoperative survival in this group [5, 21, 22] . The data in the present study confirm the efficacy of nephrectomy with IVC thrombectomy in achieving long-term [5, 23] and have been shown to vary with thrombus level [5] . Our outcomes (6% perioperative mortality, 43% early complications, 18% major complications) compare well with the published literature. Our complication rate is at the upper limit of the reported range, but this probably stems from our stringent reporting methods [14] .
The group from the University of Miami has described their success in managing IVC thrombi without the use of bypass techniques extensively, theoretically reducing the risk of associated coagulopathy and neurological sequelae [10, 11] . We confirm, in a subgroup of our patients, that even complex intra-hepatic and supra-hepatic tumour thrombi could be addressed without circulatory bypass. Bypass techniques have not been used in MSKCC for the resection of caval thrombi since 1996.
Patients with clinical evidence of supradiaphragmatic caval wall invasion or extensive atrial involvement are referred to other institutions for bypass. This has been necessary once in the last 5 years. Other groups have advocated the use of intraoperative TEE to monitor thrombus level, particularly during resection of level 3/4 thrombi [24] . We believe it is most useful in patients with the indications for cardiopulmonary bypass listed earlier. Thus while TEE is available intraoperatively, it is not used routinely at MSKCC. There were no perioperative fatalities among the 10 patients with level 3/4 thrombi. In one patient, thombectomy could not be completed because of clinically undetected, extensive involvement of the intra-hepatic caval wall by tumour. Circumferential invasion along the length of the intra-hepatic IVC made it unlikely that this patient would have been successfully resected even on cardiopulmonary bypass. Of 10 patients with level 3/4 thrombi, seven were deemed completely resected at the time of surgery, and seven of 10 survived more than 5 years or were alive at last follow-up. In addition, two patients with IVC recurrences (one initially resected elsewhere, one from the present series) underwent successful resection of their recurrence using the technique outlined earlier. Both patients remained alive at last follow-up, 1.5 and 8 years after resection, respectively.
The present study is a retrospective review of a single institutional experience and, as such, is subject to certain biases and limitations. The complication data are limited by the information available in the patients' charts. Emergency room visits and outside admissions might not have been reported by patients and thus might not have been captured by our review. We are also limited by the small number of patients in the present series. Finally, it is possible that the absence of cardiopulmonary bypass support could reduce the number of level 4 thrombi in the present series and potentially skew the survival outcomes.
In conclusion, RCC with associated caval thrombus presents a rare but substantial surgical challenge. In the present study, we show, as others have, that complete surgical resection could result in long-term diseasefree survival in these patients. Bypassassisted approaches to caval thrombectomy could still be necessary when complex vascular reconstruction is anticipated. The approach must be selected with consideration for the tumour anatomy on clinical staging and the surgeon's experience. However, the present report provides further evidence that resection of level 3/4 thrombi could be safely accomplished without the use of intraoperative circulatory bypass, and with satisfactory oncological outcomes.
